BRIEF—Mike Heffernan named chairman of NMD Pharma's board

Danish clinical-stage biotech NMD Pharma today announced that Mike Heffernan has been appointed as chairman of the board of directors, succeeding Patrick Vink, who has served as chairman since 2015.

Mr Heffernan is a successful entrepreneur with over 30 years’ experience building development-stage and commercial biopharmaceutical companies. He is the chief executive and chairman of the USA-based oncology company Avenge Bio, which he co-founded in 2019.

He is also a board member of numerous public and private biotech companies including Biohaven Pharmaceutical, Synlogic, Trevi Therapeutics, Collegium Pharmaceutical, and K36 Therapeutics.

Mr Heffernan has held numerous previous leadership positions during his career.

Prior to co-founding Avenge Bio, he founded Collegium Pharmaceutical, a specialty pharmaceutical company in 2018 where he served as CEO and currently serves as chairman.

Other previous leadership positions include CEO of Onset Dermatologics, a commercial-stage dermatology company that he founded and spun out of Collegium to create PreCision Dermatology, which was acquired by Valeant in 2014.

He also co-founded and served as CEO of Clinical Studies, a pharmaceutical contract research organization that was acquired by PhyMatrix Corp in 1997.